| Patents for A61P 5 - Drugs for disorders of the endocrine system (28,908) |
|---|
| 07/12/2000 | EP1017378A1 Amide derivatives for the treatment of diseases mediated by cytokines |
| 07/12/2000 | EP1017279A1 Methods for regulating trka expression |
| 07/12/2000 | EP0792289B1 Low molecular weight peptidomimetic growth hormone secretagogues |
| 07/12/2000 | CN1259959A GnRh antagonists being modified in positions 5 and 6 |
| 07/12/2000 | CN1259944A Treatments of prophylaxis of prostatic cancer and benign prostatic hyperplasia |
| 07/11/2000 | US6087378 The active benzo(b)thiophene compounds for treating osteoporosis and cardiovascular disorders, especially hyperlipidemia |
| 07/06/2000 | WO2000039283A1 Use of cd40 engagement to alter t cell receptor usage |
| 07/06/2000 | WO2000039279A2 Dna encoding a human melanin concentrating hormone receptor (mch1) and uses thereof |
| 07/06/2000 | WO2000039278A2 Pth functional domain conjugate peptides, derivatives thereof and novel tethered ligand-receptor molecules |
| 07/06/2000 | WO2000039176A1 Hydrophilic ampholytic polymer |
| 07/06/2000 | WO2000039148A1 New 7-alpha, 17-alpha-bis-alkylated testosterone derivatives and their use in long-term therapy of androgen-dependent diseases |
| 07/06/2000 | WO2000039128A1 5ht1 antagonists for antidepressant therapy |
| 07/06/2000 | WO2000039120A2 Compounds and methods for modulation of estrogen receptors |
| 07/06/2000 | WO2000039077A2 Thyroid receptor ligands |
| 07/06/2000 | WO2000038659A1 Transdermal drug delivery system |
| 07/06/2000 | WO2000020024A3 Methods for the treatment of non-thyroid disorders |
| 07/06/2000 | WO2000017222A8 31 human secreted proteins |
| 07/06/2000 | WO2000015770A3 Human serine/threonine protein kinases |
| 07/06/2000 | CA2358687A1 Dna encoding a human melanin concentrating hormone receptor (mch1) and uses thereof |
| 07/06/2000 | CA2356986A1 Compounds and methods for modulation of estrogen receptors |
| 07/06/2000 | CA2356692A1 Hydrophilic ampholytic polymer |
| 07/06/2000 | CA2356319A1 Thyroid receptor ligands |
| 07/05/2000 | EP1015008A1 Compounds and compositions for delivering active agents |
| 07/05/2000 | EP0900234B1 21-substituted progesterone derivatives as new antiprogestational agents |
| 07/05/2000 | CN1259142A Zinc free insulin crystals for use in pulmonary compositions |
| 07/05/2000 | CN1259140A Treatment of insulin resistance with growth hormone secretagogues |
| 07/05/2000 | CN1259137A Estra-5(10), 7-dienes with estrogenic activity |
| 07/05/2000 | CN1259120A Calcilytic compounds |
| 07/05/2000 | CN1258510A Snail health products making process |
| 07/05/2000 | CN1054133C 17-spiromethylene steroids |
| 07/04/2000 | US6083978 Compounds with a sulfamate group |
| 07/04/2000 | US6083956 Optically pure androgen mediator |
| 07/04/2000 | US6083941 Inhibition of NMDA receptor activity by pregnenolone sulfate derivatives |
| 07/04/2000 | US6083936 Treatment of estrogen-dependent disorders such as estrogen-dependent cancers; also useful in diagnostic techniques such as magnetic resonance imaging and magnetic resonance spectroscopy |
| 07/04/2000 | US6083916 Pharmaceutical product for application to uterus mucosa |
| 06/29/2000 | WO2000037474A1 Fused 1,2,4-thiadiazine derivatives, their preparation and use |
| 06/29/2000 | WO2000037430A2 Use of androgen receptor suppressors |
| 06/29/2000 | WO2000037422A2 Ion channel modulating agents |
| 06/29/2000 | WO2000037358A1 NOVEL sPLA2 INHIBITORS |
| 06/29/2000 | WO2000037109A2 Clathrates of dehydroepiandrosterone and corresponding pharmaceutical compositions |
| 06/29/2000 | WO2000037103A2 Compounds for intracellular delivery of therapeutic moieties to nerve cells |
| 06/29/2000 | WO2000037098A1 Shelf-stable formulation of glucagon-like peptide-1 |
| 06/29/2000 | WO2000037089A1 Cyclic adenosine diphosphate ribose analogues for modulating t cell activity |
| 06/29/2000 | WO2000037083A1 Oral antiestrogen pharmaceutical composition |
| 06/29/2000 | WO2000037065A2 Endocrine therapy for breast cancer: combined treatment with tamoxifen plus alkyl pcdfs |
| 06/29/2000 | WO2000037053A1 Large molecule drug delivery system using aerosolized membrane-mimetic amphiphiles |
| 06/29/2000 | WO2000024437A8 Textured and porous silicone rubber |
| 06/29/2000 | WO2000009073A3 Blood-brain barrier therapeutics |
| 06/29/2000 | DE19860719A1 Neue Testosteronderivate und ihre Verwendung zur Langzeittherapie von Androgen-abhängigen Erkrankungen New testosterone derivatives and their use for long-term therapy of androgen-dependent diseases |
| 06/29/2000 | CA2356624A1 Endocrine therapy for breast cancer: combined treatment with tamoxifen plus alkyl pcdfs |
| 06/29/2000 | CA2356454A1 Compounds for intracellular delivery of therapeutic moieties to nerve cells |
| 06/29/2000 | CA2356159A1 Novel spla2 inhibitors |
| 06/29/2000 | CA2355148A1 Clathrates of dehydroepiandrosterone and corresponding pharmaceutical compositions |
| 06/29/2000 | CA2353907A1 Fused 1,2,4-thiadiazine derivatives, their preparation and use |
| 06/29/2000 | CA2353848A1 Large molecule drug delivery system using aerosolized membrane-mimetic amphiphiles |
| 06/28/2000 | EP1013278A1 The extract of pine needle and the use thereof |
| 06/28/2000 | EP1012290A1 EXPRESSION OF GONADOTROPINS IN $i(DICTYOSTELIUM) |
| 06/28/2000 | EP1012242A1 Human sigma receptor |
| 06/28/2000 | EP1012189A1 Treatment of obesity |
| 06/28/2000 | EP1012177A1 Estrogen receptor |
| 06/28/2000 | EP1012171A1 Modulating the activity of hormones or their receptors - peptides, antibodies, vaccines and uses thereof |
| 06/28/2000 | EP1012151A1 Heterocyclyl-substituted ring-fused pyridines and pyrimidines as corticotropin releasing hormone (crh) antagonists, useful for treating cns and stress-related disorders |
| 06/28/2000 | EP1011724A1 Regulation of osteoclast formation by inhibition of osteoblastic stem cell factor |
| 06/28/2000 | EP1011684A2 Solid oral dosage form comprising a combination of metformin and glibenclamide |
| 06/28/2000 | EP1011682A2 Hormonal contraceptive |
| 06/28/2000 | EP1011667A1 Antagonists of gonadotropin releasing hormone |
| 06/28/2000 | EP1011637A1 Modulation of drug loading in multivesicular liposomes |
| 06/28/2000 | CN1258286A Non-steroidal (hetero) cyclically substd. acylanilides with mixed gestagen and androgen activity |
| 06/28/2000 | CN1053886C Naphthyl compounds, intermediates and their preparing method and use |
| 06/27/2000 | US6080765 Pharmaceutical composition |
| 06/27/2000 | US6080755 1,9-diazabicyclo[4.3.0]nona-3,8-diene derivatives |
| 06/27/2000 | US6080754 For treatment and prophylaxis of estrogen related syndromes and disorders |
| 06/27/2000 | US6080735 Estra-1,3,5(10)-trien derivatives, processes for their preparation and pharmaceutical compositions containing these compounds |
| 06/22/2000 | WO2000036103A1 Cytokine receptor chain |
| 06/22/2000 | WO2000035458A1 Pharmaceutical aerosol formulations containing fluoroalkanes and budesonide |
| 06/22/2000 | WO2000014106A9 Novel bag proteins and nucleic acid molecules encoding them |
| 06/21/2000 | EP1009772A1 Monoclonal antibodies that bind testosterone |
| 06/21/2000 | EP1009755A1 Steroid sulfatase inhibitors and methods for making and using the same |
| 06/21/2000 | EP1009393A2 Transdermal therapeutic system comprising a reservoir-type pressure-sensitive adhesive layer and a back layer with uni-directional resilience |
| 06/21/2000 | CN1256923A Traditional Chinese medicinal composition for stopping drug taking and preparation process thereof |
| 06/20/2000 | CA2001618C Gestodene-containing agent for transdermal administration |
| 06/15/2000 | WO2000034468A2 Muc-1 antagonists and methods of treating immune disorders |
| 06/15/2000 | WO2000034334A1 DNA ENCODING A MAMMALIAN RECEPTOR (fb41a) AND USES THEREOF |
| 06/15/2000 | WO2000034332A1 Glp-1 analogues |
| 06/15/2000 | WO2000034331A2 Analogues of glp-1 |
| 06/15/2000 | WO2000034306A1 17β-ACYL-17α-PROPYNYL-11β-ARYLSTEROIDS AND THEIR DERIVATIVES HAVING AGONIST OR ANTAGONIST HORMONAL PROPERTIES |
| 06/15/2000 | WO2000034303A1 METHODS OF MODULATING TUMOR NECROSIS FACTOR α-INDUCED EXPRESSION OF CELL ADHESION MOLECULES |
| 06/15/2000 | WO2000034236A1 REVERSIBLE AQUEOUS pH SENSITIVE LIPIDIZING REAGENTS, COMPOSITIONS AND METHODS OF USE |
| 06/15/2000 | WO2000033877A1 Anhydrous topical skin preparations |
| 06/15/2000 | WO2000033839A1 Non-peptide antagonists of glp-1 receptor and methods of use |
| 06/15/2000 | WO2000033834A1 Use of isatin derivatives as ion channel activating agents |
| 06/15/2000 | WO2000033817A1 Phospholipid compositions |
| 06/15/2000 | WO2000033809A1 Compositions containing a peptide and polylactic-glycolic acid suitable for preparing subcutaneous implants with an extended release period |
| 06/15/2000 | CA2778047A1 Analogues of glp-1 |
| 06/15/2000 | CA2354644A1 Muc-1 antagonists and methods of treating immune disorders |
| 06/15/2000 | CA2354142A1 Reversible aqueous ph sensitive lipidizing reagents, compositions and methods of use |
| 06/15/2000 | CA2352178A1 Phospholipid compositions |
| 06/15/2000 | CA2350887A1 Non-peptide antagonists of glp-1 receptor and methods of use |
| 06/14/2000 | EP1007074A1 Hypothalamus-specific polypeptides |
| 06/14/2000 | EP1006794A1 A method for treating or preventing alzheimer's disease |